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Stem cell therapy is being intensely investigated within the last years. Expectations are high regarding mesenchymal stem cell
(MSC) treatment in translational medicine. However, many aspects concerning MSC therapy should be profoundly defined.
Due to a variety of approaches that are investigated, potential effects of stem cell therapy are not transparent. On the other
hand, most results of MSC administration in vivo have confirmed their safety and showed promising beneficial outcomes.
However, the therapeutic effects of MSC-based treatment are still not spectacular and there is a potential risk related to MSC
applications into specific cell niche that should be considered in long-term observations and follow-up outcomes. In this review,
we intend to address some problems and critically discuss the complex nature of MSCs in the context of their effective and safe
applications in regenerative medicine in different diseases including graft versus host disease (GvHD) and cardiac, neurological,
and orthopedic disorders.
1. Introduction
Mesenchymal stem cells (MSC) are of clinical interest
because of their potential use in autologous transplantation.
A lot of clinical trials using MSCs have been accomplished,
and many others are being under examination. Recent
reports demonstrated that more than two thousand patients
received autologous or culture-expanded allogeneic MSCs
for the treatment of different diseases [1]. In most cases,
MSC therapy was quite efficient. However, the potential risk
of MSC transplantation should be considered in terms of the
long-lasting observations. Numerous reports from in vitro
and in vivo studies provided the evidence about MSC differ-
entiation into certain cell types [2]. However, a growing evi-
dence from recent studies strongly suggests to focus on MSC
paracrine properties including the release of extracellular
vesicles containing numerous mRNAs, regulatory miRNAs,
multiple bioactive proteins and compounds [3], and the
production and secretion of a large number of regulatory
substances rather than MSC direct differentiation and cell
replacement [4]. The main therapeutic effects of MSCs are
now attributed to the stimulation of several endogenous
repair processes in injured tissues in vivo by secreted factors
as well as the modulation of immune response, which trans-
lates into a positive outcome of MSC-based therapies.
Another important aspect is the cellular heterogeneity of
MSCs, which makes consistent conclusions about MSC ther-
apeutic potential difficult, because the obtained results are
frequently variable and may depend on the different MSC
origin as well as harvesting and culture procedures [5]. At
the same time, it makes MSCs a very interesting type of cells
to be studied due to their complex nature. So far, there is no
precise MSC definition, and already existing definitions only
partially reflect the functional properties of these cells [6].
Due to the great interest in MSCs, a large number of publica-
tions explore the biological properties of these cells [7].
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Several in vitro studies are aimed at defining compound and
overlapping molecular mechanisms that may be involved in
therapeutic MSC action in vivo. Besides these facts, the
results of other multiple in vitro studies pave the way to pos-
sible modifications of the ex vivo culture environment and
MSCs themselves to further increase their regenerative
potential [7], and consequently to achieve better results in
in vivo studies.
In the present article, we discuss the potential side effects
of exogenous MSC administration in vivo. In particular, we
focus on GvHD [8] and cardiologic [9], neural [10], and
orthopedic [11] patients, where MSC administration may
have limited beneficial effects and provide some side effects
for the recipient (Figure 1). We believe that, discussing some
adverse aspects of MSC activity after their transplantation,
we create a more reliable and complete view of MSC role in
regenerative medicine.
2. Heterogeneity of MSCs
There are reports that demonstrated that the quality of the
human MSC product depends on the isolation and culture
methods as well as the age, genetic traits, and medical history
of the donor [12–15]. It seems that the most important factor
to consider is the age of a donor so the autologous transplan-
tation can have some limitations. The challenging issue is
how to expand MSCs from elderly patients to obtain an effi-
cient number of therapeutic cells. Moreover, it is difficult to
isolate an effective population of MSCs from patients with
some diseases including diabetes, rheumatoid arthritis, and
other inflammatory diseases, thus regarding autologous rea-
sons (where the cells isolated from the patient might be
affected by the disease); the researchers suggest possible loss
of therapeutic function by these cells [15]. Baptista and col-
leagues demonstrated that MSCs obtained from people with
obesity have significantly impaired proliferation and differ-
entiation potential [16]. However, due to some problems
with autologous sources, we should consider immunologi-
cal aspects of allogeneic MSC transplantation. Historically,
MSCs have been shown to exhibit low immunogenic poten-
tial in vitro because of their limited expression of MHC I
molecules, the lack of MHC II expression, and costimulatory
molecules. Recent studies suggest that MSCs may not be
“immune privileged” as assumed previously. It was shown
that MSCs are no longer considered immunologically silent
in vivo [17, 18]. Moreover, use of allogeneic MSCs has some
limitations, considering risk factors including immunological
response [19].
3. Potential Side Effects of Exogenous MSCs
after Their Administration In Vivo
The past decade has seen an explosion of research which
directed at evaluation of mesenchymal stem cells as a cellular
therapy in different debilitating diseases; however, a compre-
hensive analysis is needed to explain the discrepancies in
clinical trials examining MSC treatment. Many negative
effects are probably unreported, but they can occur. Stem cell
therapies are complicated and can have serious side effects. A
case report was published recently demonstrating that the
patient developed a large tumor-like mass inside the spinal
cord after 8 years of olfactory mucosa cell transplantation
[20]. Although the trial was performed with the use of dif-
ferent adult stem cells than the MSC type, one should take
into account that the potential mechanism of neoplastic
transformation could be similar in case of MSC transplanta-
tion. Thus, more control investigations have to be performed
with MSC samples prior to their transplantation to the spe-
cific niches in different tissues. In the following subsections
of review, we will focus on side effects of MSCs therapy in
different diseases.
3.1. MSCs as Advanced Therapy Medical Products.MSCs are
now determined as Advanced Therapy Medicinal Products
(ATMP) and guidelines from the American Code of Federal
Regulation of the Food and Drug Administration and the
European Medicines Agency, and the network of national
agencies defines the requirements for suitable production
of these cells. These guidelines, generally called “Good
Manufacturing Practices” (GMP), consist of many recom-
mendations about cell culture procedures including valida-
tion and quality control to ensure optimal reproducibility,
efficiency, and safety of the final medical product. Another
classification, defined by the Food and Drug Administra-
tion guidelines, defines cultured cells as “minimally” and
“more than minimally” manipulated which describe proce-
dures “that might alter the biological features of the cells.”
However, minimal manipulation conditions have not been
precisely defined for the collection and isolation of various
sources of MSCs [21–23]. Most of cell culture protocols that
have been reported so far are inadequate, because of the use
of supplemented cell culture media, enzymatic treatment,
and long-term cell expansion that are known to change the
quality of MSCs [21]. The results published by Codinach
and collaborators showed bioprocess engineering applica-
tion for bone marrow-derived MSC (BM-MSC) isolation,
expansion, validation, and production for clinical use. The
authors tested 48 batches of BM samples from the iliac crest
for autologous transplantations [20]. The manufacturing
process contained diverse steps including collection, isola-
tion, trypsinisation, and all quality control that is needed
for confirmation of functionality, safety, and potency of
MSCs. In conclusion, Codinach et al. confirmed that all steps
are effective and reproducible and most importantly safe for
clinical use [23]. Nevertheless, validation of optimal isolating
and culturing protocols according to GMP requirements is
still needed.
3.2. MSCs to Treat or Prevent Graft-versus-Host Disease.
Graft-versus-host disease (GvHD) accompanies allogeneic
hematopoietic stem cell transplantation (HSCT) in many
patients. In GvHD treatment, the corticosteroids are used;
however, this therapy is not effective in all patients [8].
Immunomodulatory properties of MSCs reported in experi-
mental studies suggest their application in GvHD treatment.
Indeed, recently MSC transplantation was performed to pre-
vent or to treat GvHD especially in those patients who are
unresponsive to steroids [24]. However, despite of MSC
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applications in many clinical trials, the controversy still exists
for the profits of such a therapy. Although the reduction of
inflammatory processes is noticed after MSC implantation,
downregulation of immune response could augment the
chance of infections, especially in patients receiving immu-
nosuppressive therapy after HSCT [25]. It was reported that
the infusion of MSCs might dangerously constrain antimi-
crobial immune response [26]. von Bahr et al. have shown
enhanced complications in a retrospective study in GvHD
patients due to the infections in a short period of time
after different source derived (BM/PBSCs/CB) MSC trans-
plantation, causing the mortality to reach 54% [27]. The
infection-related mortality was high even after GvHD deter-
mination. It may be related to the long immunosuppressive
effect of MSCs. The clinical trial announced by Ning et al.
showed that the occurrence of acute and chronic GvHD in
patients after MSC transplantation was lower than in patients
without MSC graft, but the episodes of severe infections
were higher in patients who have received HSCT and bone
marrow-derived MSCs than in the control group not
receiving MSCs. Among patients, two of them manifested
CMV interstitial pneumonia and/or fungal infection [28].
Forslöw et al. suggest an increased susceptibility to pneumo-
nia observed in patients with GvHD after MSC infusion [29].
The retrospective study of patients with steroid-refractory
GvHD receiving MSCs announced high CMV peak viral load
[27]. This is the contradiction with earlier in vitro experi-
ments which depicted that cytotoxic T cells against CMV
were restricted to BM-MSC effect [30]. Recently, Thanunchai
et al. have postulated that in viral infections human BM-
MSCs might also act as viral transmitters [31]. Moreover, in
different experimental models it was shown that BM-MSCs
encourage tumor growth by modulating the tumor microen-
vironment [32, 33]. In a pilot clinical study using MSCs to
prevent GvHD in patients with hematologic malignancies,
MSCs decreased GvHD development but the relapse rate in
patients was over the control group. Out of 10 patients, 6 of
them in the MSC group suffered from tumor relapse in com-
parison to 3 of 15 in the control group not receiving MSCs
[28]. The protumorigenic effects revealed by MSCs are prob-
ably related to their immunosuppressive properties, the
modulation of tumor stroma, and their ability to transform
themselves into malignant cells. However, the experiments
confirming the tumorigenic potential of MSCs were con-
ducted on rodent models. Up to now, there is no existing data
displaying malignant transformation of humanMSCs. More-
over, it is not clear whether human MSC aneuploidy is not
related with senescence or transformed population of cells
[34]. The existent data concerning the direct in vitro trans-
formation of MSCs were retracted due to contamination with
other cell lines. It has been also reported that transplantation
of MSCs from diverse sources (BM, placenta, or umbilical
cord blood) to haploidentical mice did not prevent or treat
GvHD [35]. The suggestion exists that MSCs may lose their
immunosuppressive properties in mismatched settings,
which was proved on murine cells [36]. Furthermore, the
Muroi et al. study showed that grafted BM-MSCs in the
phase II/III study for acute GvHD does not protect the devel-
opment of chronic GvHD [37].
Based on the above mentioned studies, it needs to be
highlighted that MSC transplantation for GvHD preven-
tion or therapy is relatively safe and efficient in steroid-
refractory GvHD, but infections remain a major risk of
patients. Furthermore, it was shown that MSCs transplanted
for established GvHD can cause an increased relapse [28].
In the recent paper published by Ringden et al.’s group,
the authors mention several adverse effects occurring after
transplantation of decidual placenta-derived MSCs in the
treatment of GvHD. Among them, relapse; pneumonia;
bacterial, viral, and fungal infection; and graft failure are
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Figure 1: The scheme of potential risks of adverse events during MSC transplantation.
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listed [38]. It seems that the new strategy supporting a high
rate effect of MSCs against GvHD with a low adverse effect
to the patient is warranted in large-scale randomized stud-
ies. The research carried by different laboratories focuses
on the development of new MSC drugs. One of the first reg-
istered MSC-based drugs recommended to use for treatment
of GvHD was Prochymal. Recently, Mesoblast recruited
patients for clinical phase 3 for treatment of GvHD and
others like chronic heart failure and chronic low back pain.
The company developed the strategy of isolation and bank-
ing of BM-MSCs derived from healthy donors. However, this
product is not yet approved by FDA. Similarly iPSC-derived
MSCs were proposed by Cynata’s therapeutics. Investigation
is within clinical phase 1; however, it is still hard to evaluate
the results due to the early stage of research.
3.3. MSCs in Cardiology. Cardiovascular diseases (CVDs)
affecting both heart tissue and circulatory system, especially
blood vessels, represent today one of the main causes of mor-
tality in Western countries. According to the report from
the American College of Cardiology, CVDs caused close to
17.3 million deaths worldwide in 2008 and the predictions
indicate an increase in the mortality to about 25 million
deaths per year by 2030 [39]. Since heart tissue exhibits
limited endogenous potential for cardiac cell proliferation
and repair, multiple stem cell-based therapeutic approaches
have been already tested in several preclinical animal models
and clinical trials in humans, indicating potential beneficial
effects of such treatment on the heart anatomy and functions
in different CVDs [40, 41]. Experimental cardiology repre-
sents today the clinical field greatly relaying on various
novel approaches employing cell therapy products that
may enhance cardiac tissue repair and regeneration [42].
Adult stem cells including MSCs have been indicated as
one of the most promising therapeutic cells for myocardial
repair and have been also widely used as potential therapeutic
cells in several cardiovascular diseases [43, 44]. Although
MSCs exhibit great prochondrogenic, osteogenic, and adi-
pogenic differentiation potential, several studies provided
evidence that in optimal culture conditions in vitro or in car-
diac in vivo niche, MSCs may also give rise to other highly
specialized tissue types including cardiomyocytes and endo-
thelial cells [45–47]. Considering these findings, MSCs have
been extensively tried as a source of cells replacing damaged
myocardial tissue in vivo, in both acute and chronic heart
injury events, confirming the trans-differentiation capacity
of MSCs into cardiac and endothelial cells [43, 44]. Neverthe-
less, the differentiating capacities of MSCs into functional
endothelial and cardiac cells in vivo have not been well fully
confirmed. Moreover, it is hard to confirm the presence of
transplanted, integrated cells in any tissue in vivo, due to
the lack of specific MSC markers [48]. However, growing
recent evidence from multiple laboratories strongly indicates
predominant paracrine activity of MSCs after transplanta-
tion, promoting cardiac cell survival, proliferation, and dif-
ferentiation by MSC-derived secreted bioactive factors and
extracellular vesicles (EVs) [49–51]. Thus, these two major
mechanisms including (1) direct MSC differentiation into
cardiac and endothelial cells and (2) paracrine activity
mediated by MSC-derived soluble molecules and vesicles
are currently considered as major factors mediating benefi-
cial effects of MSC-based therapies in CVDs [49–51]. It is
believed that most of the beneficial effects after MSC trans-
plantation are related to their paracrine impact on endoge-
nous cells that results in an increase in vasculogenesis and
angiogenesis as well as enhanced cell survival.
Although MSCs, as adult cells, represent one of the safest
populations of stem cells with nearly no risk of endogenous
teratogenic potential characterizing normal pluripotent stem
cells such as ESCs and iPS cells, the in vivo applications of
MSCs into cardiac tissues may still potentially lead to some
adverse effects following their transplantation [9, 52, 53].
The few reported concerns regarding MSC safety are related
to their possible (1) proarrhythmic and (2) tumorigenic
capacity in a heart tissue as well as to (3) differentiation into
undesirable tissue type [9, 52, 53]. Price and colleagues
reported that BM-MSCs infused intravenously in pigs with
acute ischemia/reperfusion injury improves heart function
parameters and limits adverse wall thickening, but it may also
negatively impact on electrophysiological properties of the
myocardium suggesting a proarrhythmic potential of these
cells. However, the beneficial effects of injected MSCs on
heart function and anatomy observed in this study were
greater than the noted arrhythmic events, and eventually
the authors positively concluded on the MSC efficacy in their
heart repair model [9]. Importantly, on the other hand,
multitude clinical studies involving patients suffering with
acute or chronic ischemic heart diseases have reported very
limited or no adverse effects of MSCs on myocardial electri-
cal properties following the treatment as summarized in
several reviews and meta-analysis reports [41, 54]. Thus,
the reported events of proarrhythmic activity of MSCs are
rather rare; however, it should be considered and evaluated
especially in clinical trials with humans as a potential risk
indicated by some animal studies. Some of the unsolved
problems in clinical research in cardiology may be also par-
tially related to insufficient placebo groups. However, when
compared to other stem and progenitor cells used for heart
repair including skeletal muscle myoblasts extensively stud-
ied in the early 2000s, MSCs may be definitely considered
as cells with limited risk of arrhythmia in cardiac tissue [55].
A similar risk of undesirable tissue formation in the sites
of MSC transplantation may be related to their innate capac-
ity to predominantly give rise into bone and cartilage cells.
Although the unique microenvironment of the cardiac niche
consists of several mediators directing stem cell fate and dif-
ferentiation [56], it has been shown in some single reports
that MSCs transplanted into heart tissue may undergo mis-
differentiation into other noncardiac cells [52]. Indeed, some
experiments conducted on animal models proved episodes of
calcification and ossification of heart tissue and injured
abdominal aorta after BM-MSC administration [53, 57]. It
must be considered that unreliable published data may pro-
vide some problems for the field of stem cell practical appli-
cation as it was in the recent case of cardiac progenitors.
Moreover, not carefully designed studies might have a nega-
tive influence on the results of clinical trials. Furthermore,
several studies underline that effectiveness of therapy may
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be influenced by quality of stem cells including their senes-
cence status [58].
The other novel approaches to limit the potential risks
related to cellular properties of stem cells including MSCs
would be a use of their acellular MSC products such as extra-
cellular vesicles (EVs). MSCs are believed to secrete EVs
loaded with regulatory factors like miRNA, mRNA, proteins,
growth factors, and cytokines. Several recent studies includ-
ing our own data indicates that MSC-derived EVs represent
bioactive specimens released by MSCs that may become a
new effective and safe therapeutic tool in heart repair and
may gradually replace the whole stem cell-based therapies
in the near future [51, 59].
3.4. MSCs in Neurology. There is great interest in the
establishment of the effective denouement in the field of
cell-based therapies with the future application for neurode-
generative diseases. Multiples studies are being undertaken
on the administration of MSCs in various neurological dis-
eases so far. However, there is a growing data set that MSC
therapy is still ineffective and even might be harmful in some
cases. There are already reports from clinical trials stating the
absence of the substantial beneficial therapeutic effect of
transplanted MSCs.
In the case of amyotrophic lateral sclerosis (ALS), phase I
study results did not show notable positive effects of exoge-
nous MSCs deposited to the spinal cord. The main conclu-
sion in most of the clinical trials in ALS therapy with the
use of MSCs was limited to the statement concerning safety
of a treatment. In a study performed by Syková and col-
leagues, where BM-MSCs were transplanted intrathecally, a
beneficial outcome was visible only in few of patients and
was restricted to the short time following transplantation
[10]. The cause of such result might be a result of short sur-
vival of the cells after implantation or the differentiation state
of transplanted MSCs. Repeated transplantation might be
crucial in order to achieve better results; however, this fact
may be problematic in terms of the manufacturing process.
Another phase I study with the intrathecal autologous
BM-MSC injection brought light to the mild adverse over-
coming reactions immediately after exogenous cell deposi-
tion, such as fever, pain, and headache; nevertheless, there
were no major effects of therapy [60]. The group of Staff
and colleagues performed intrathecal adipose-derived MSC
injection in treatment of ALS. Similarly, the authors did not
notice any spectacular improvements in treated patients
and postulated mitigation in enthusiasm toward the effec-
tiveness of therapy [61]. To add with, intramuscularly and
intrathecally transplanted MSCs aspirated from BM were
found to be safe and stimulated release of autologous neuro-
trophic factors; however, such approach contributed to some
disease regression only in half of the patients in the following
6-month period [62]. Nevertheless, earlier studies of Karussis
and coworkers where BM-derived MSCs were injected intra-
venously and intrathecally did not bring any positive effects
in ALS patients [63].
In case of stroke, one of the main topics related to the effi-
cient cell treatment is the delivery route to the damaged part
of the brain. For this reason, the blood circulation system is
considered to be the appropriate one. However, one should
be aware of the how the administration of the exogenous cells
is performed in order to assure the safety for the patient on
the one hand and to guarantee the maintenance of the good
quality of therapeutic cells during transplantation procedure
on the other hand [64]. Cui and colleagues revealed that cell
clump formation before injection was increasing proportion-
ally with the increasing time of cell storage duration in sus-
pension. In addition, due to their size, MSCs might elicit
serious vascular obstructions after intravascular delivery.
The size of MSCs in the monolayer culture in vitro increases
along with the passage number; a solution may pose 3D
spheroid culture in vitro that makes MSCs smaller again
[65]. The failure of a positive outcome after systemic admin-
istration of MSCs in stroke was confirmed by another study,
where intravenously injected hBM-MSCs in a mouse stroke
model contributed to the enhancement of cell proliferation
in neurogenic areas just to a small extent. Furthermore, nei-
ther detectable decline in infarct size nor beneficial clinical
symptoms were reported [66]. Even more, MSCs intra-
arterially delivered in a mouse model of ischemia did not
contribute to the functional recovery improvement and addi-
tionally might promote the risk of cerebral lesions [67].
These multifocal lesions contributed to the significant cere-
bral blood flow drop, which was a result of the obstruction
of small vessels by the exogenous cells in the circulatory sys-
tem, conjointly eliciting a profound risk of secondary embo-
lism in stroke brains. These data are reinforced by another
study where the intra-arterially delivered human BM-MSCs
were transiently present in the injured brain, but this phe-
nomenon was not accompanied with behavioural improve-
ment in a rat stroke model [68]. A similar outcome was
observed by Oh and coworkers that intra-arterially delivered
MSCs isolated from adipose tissue exerted a just transient
effect shortly after their commitment to the target area, and
there was no further functional improvement reported; thus,
it seemed that cell replacement did not occur [69]. Finally, an
intra-arterial route failed to deliver MSCs to the brain paren-
chyma in an Alzheimer’s disease mouse model. Presumably,
systematically injected human umbilical cord blood MSCs
would not cross the brain blood barrier, which is not injured
in this disorder [70].
In the case of multiple sclerosis (MS), an intravenous
route of BM-MSC delivery turned out to be not the most sat-
isfactory, because this way of application of the cells failed for
mouse MSCs in mouse models of MS. MSCs were found
mainly in the lungs and liver with the parallel MSC absence
in the inflammatory lesions in the central nervous system.
To add with, no beneficial effects were reported [71]. An
intra-carotid way of delivery was explored to deliver MSCs
to the brain parenchyma in a rat model of Parkinson’s dis-
ease. However, the number of engrafted BM-derived MSCs
in the brain was minimal due to the lack of ability to cross
the brain blood barrier by these cells [72]. Even deposited
directly to the brain parenchyma, exogenous MSCs isolated
from BM miscarried their therapeutic infliction and failed
to differentiate into lost neurons and were eliminated up to
one month after administration [73]. These results are con-
cordant with the outcome obtained in a mouse model of
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MS, where human BM-MSCs were implanted intraventricu-
larly or exactly into the lesions of the corpus callosum. MSCs
did not modulate positively any regenerative functions and
remyelination resulting in no direct beneficial effect [74].
3.5. MSCs in Orthopedics. Numerous studies with different
animal models of orthopedic diseases have documented
the multipotency properties of MSCs, showing their abilities
for differentiating into a variety of tissues such as muscle,
bone, cartilage, and tendon. However, against the initial
assumptions that the therapeutic effects of MSCs depend on
their abilities for cell replacement, recent studies showed
that paracrine function of MSCs is the main mechanism by
which they participate in tissue repair [75]. MSCs have been
reported to exhibit immunosuppressive and immunomodu-
latory properties through the secretion of specific factors
that can modulate inflammatory responses after orthope-
dic injuries [76]. Nevertheless, the widespread mechanism
of MSC action in orthopedic applications has not been
completely established [77].
Many reports summarized the role of MSCs in osteoar-
thritis (OA) therapy; however, the results of these studies
are quite inconsistent. Recent published data reported that
several early-stage clinical trials, testing an intra-articular
infusion of MSCs into the knee of patients with OA, were
not completed; moreover, the optimal dose and the route of
cell administration are still to be established [11]. Filardo
and colleagues reported that, despite a growing body of evi-
dence in the biological approach of cartilage regeneration,
the understanding of this merit is still insufficient [78]. Fur-
ther randomized controlled trials are definitely required to
estimate the potential of MSCs in cartilage repair and to eval-
uate advantages and disadvantages of stem cell treatment.
Several experiments done in animal models of knee OA have
shown that MSC therapy may delay progressive degeneration
of the joint [79, 80]. In a rabbit model, it was demonstrated
that single intra-articular infusion of synovial MSCs into
the knee leads to cellular adherence close to meniscal defect
and supported meniscal regeneration [81]. Another study
conducted in dogs demonstrated that repeated local delivery
of allogeneic MSCs exerted systemic immunomodulatory
effects [82]. Most of human studies support the notion that
the short-term application of MSCs is safe and feasible; how-
ever, further experiments are needed. Importantly, we still
need a clear evidence confirming efficacy of MSC transplan-
tation in patients with OA. In randomized controlled clinical
trials, MSC injection applied in the treatment of knee osteo-
arthritis showed its efficacy [83, 84]. Despite these results
coming from clinical trials, a recent systematic review by
Pas and colleagues does not recommend MSC injections for
knee OA because of nonconvincing evidence data. Further-
more, the results quoted by Shim et al. and Pas et al.’s groups
revealed that after MSC injections in knee OA treatment,
only few cells survived in the place of injection [85, 86].
According to Veronesi et al., the efficacy of MSCs used
in the treatment of cartilage disease depends on employed
procedure. Moreover, the number of cells may differ
between 3.8-11 2 × 106 which determines the time of cul-
ture and type of application in osteochondral defects
[87]. In addition, an optimal therapeutic dose of cells, coad-
juvants, and source of harvesting has not been optimized yet
[83]. MSC applications in cartilage repair have an important
bias limitation related to the placebo, as the tissue harvest-
ing procedure makes difficult to perform a blinded designed
study [78]. Thus, new studies employing MSC-based spec-
imens for orthopedic patients have to be performed with
more caution and in controlled ex vivo preparation condi-
tions, to eventually evaluate their therapeutic efficacy in
these patients.
Multiple studies suggest that besides the potential effect
of MSCs on tissue regeneration, these cells may also be signif-
icantly involved in the process of heterotopic ossification
(HO), a process of ectopic bone tissue formation in non-
bone tissues [88]. Moreover, stem cell therapies in orthopedic
trauma have identified MSCs as factors promoting high oste-
ogenic differentiation [89]. Additionally, inflammatory reac-
tion may stimulate the differentiation of mesenchymal
progenitor cells (MPCs) into osteoblasts and osteoblast-like
cells. If this process is localized in muscles or other soft tis-
sues, it may directly contribute to HO formation [90]. It
has been also reported that MSCs could be responsible for
the recurrence of HO (after surgical excision). In turn, the
excision of HO may result in reemergence of the MSC popu-
lation and signaling mechanisms that are observed in pri-
mary lesion [91].
4. Conclusions
Some recent research demonstrated limited therapeutic
effects of MSC treatment, suggesting that the direct regener-
ative potential of these cells related to their differentiation
capacity may not be as effective as previously expected. Since
several exogenous factors may greatly impact on the MSC
biological properties and eventually on their therapeutic abil-
ities, optimized protocols for MSC isolation and ex vivo
preparation for clinical use need to be well established and
standardized. Such comprehensive effort should be under-
taken into consideration by a scientific community focusing
on the practical MSC applications in tissue repair in terms
of optimal preparation of MSC-based products for more
effective therapies in patients.
The advantages of MSC applications in tissue repair, i.e.,
their safety, relatively wide differentiation capacity, and high
paracrine ability including EV release, make these cells an
important material for further investigation and develop-
ment of new approaches for cell-based therapies in future.
However, more research studies on both preclinical and
clinical levels have to be accomplished. New information
related to MSCs will help to determine the efficiency of cells
administered to the patients as a therapeutic approach.
Additional studies would also be a major contribution to
stem cell biology in general.
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